Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Issued Notice of Allowance on Lipid Nanoparticle Patent Application

Premium

Alnylam Pharmaceuticals this week said that the US Patent and Trademark Office has issued a notice of allowance for one of the company's patent applications related to lipid nanoparticles for systemic RNAi drug delivery.

Alnylam said that the patent application, No. 20100324120, is entitled “Lipid Formulation.” Alnylam said that it covers a variety of second-generation lipid nanoparticles including the so-called MC3 lipids used in the company's transthyretin-mediated amyloidosis drug ALN-TTR02 and its hypercholesterolemia treatment ALN-PCS.

Notably, ownership of the MC3 class of lipids is being disputed in an ongoing lawsuit between Alnylam and partner Tekmira Pharmaceuticals (GSN 3/17/2011).

Tekmira's management has stated publicly that Alnylam “stole” the MC3 technology.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.